

2008-006435-13 - Summary

Title: Genomics to combat Resistance against Antibiotics for Community-acquired lower respiratory tract infection (LRTI) in Europe (GRACE) work package 10: Antibiotic Trial One - a randomised placebo-controlled double-blind trial

Start Date: 2007-10-16

Study completed: 2011-04-05

Overall trial status: Completed

Main Contact: Prof Paul Little

Contact details: Primary Medical Care, University of Southampton, Aldermoor Health centre, Aldermoor Close, Southampton SO16 5ST, United Kingdom

Study design: Randomised placebo-controlled double-blind trial (Phase III)

Intervention:

1. Amoxicillin capsule, gastroenteral use, 3 g a day for 7 days
2. Placebo

Primary outcome measure

1. Deterioration of illness: return to doctor with worsening signs, or admission to hospital within 4 weeks of first consultation, measured at one year
2. Symptom severity and duration, duration of symptoms rated moderately bad until symptoms clear, measured by symptom diary (with construct validity), measured at one year

Secondary outcome measures

1. Resource use data, assessed by a review of clinical notes measured at two years
2. Quality of life outcomes for use of economic evaluation (EQ5D), measured at two years
3. Added 25/11/2014:
Antibacterial resistance in oropharyngeal streptococci measured before, immediately after and four weeks after the interventions in five networks in the third inclusion period

Countries of recruitment: Belgium, France, Germany, Italy, Netherlands, Poland, Slovakia, Slovenia, Spain, Sweden, United Kingdom

Publication list:

2012 results in: <http://www.ncbi.nlm.nih.gov/pubmed/23265995>

2014 results in: <http://www.ncbi.nlm.nih.gov/pubmed/24567620>

2015 results in: <http://www.ncbi.nlm.nih.gov/pubmed/25748415>

2015 results in: <http://erj.ersjournals.com/content/early/2015/11/05/13993003.00611-2015>